[42]IbBRAF-mutant and wild-type melanoma65M (3 or 10 mg/kg every single 14 days) + D (150 mg b.we.d.) + T (2 mg q.d.) or M (10) + T or M (10) + T ( 6 weeks just)Total = 98% (= 64)= 24)= 16)= 11)= 11)= 12)= 1)= 8)= 7)= 2)Total = 46% (= 30)= 2)= 1)= 3)= 2)= 1)= 2)= 0)Pidilizumab + rituximabWestin et al. 5)= 1)= 1)= 1)= 1)Motzer (2014) [5]IIRCC1680.3, 2, or 10 mg/kg every 2 weeksTotal: 73% (= 122)= 45)= 17)= 16)= 10)= 8)= 7)= 5)Total: 11% (= 19)= 3)= 3)= 2)= 1)= 1)= 1)Sampson (2014) [23]IGBM20 (= 10 single- agent arm)Single-agent arm: 3 mg/kg every 2 weeksTotal: 60% (= 6)= 3)= 3)Total: 0%El-Khoueiry (2015) [8]We/IIHCC470.1C10 mg/kg every 2 weeksTotal = 68% (= 32)= 9)= 8)= 8)= 7)= 7)Total = 19% (= 9)= 5)= 4)= 4)= 1)= 1)Gettinger (2015) [24]INSCLC1291, 3, or 10 mg/kg every 2 weeksTotal = 71% (= 91)= 31)= 16)= 13)= 8)= 11)= 8)Total = 14% (= 18)= 4)= 3)= 3)= 1)Rizvi (2015) [25]IINSCLC (squamous)1173 mg/kg every 2 weeksTotal = 74% (= 87)= 38)= 12)= 13)= 6)Total = 17% (= 20)= 5)= 3)= 1)= 4)Weber (2015) [1]IIIIpilimumab-refractory melanoma2723 mg/kg every 14 days versus chemotherapyTotal = 67% (= 181)= 67)= 43)= 30)= 25)Total = 9% (= 24)= 3)= 2)= 2)= 2)Brahmer [3]IIINSCLC (squamous)1313 mg/kg every 14 days versus docetaxelTotal = 58% (= 76)= 21)= 11)= 13)= 10)= 6)= 5)Total = 7% (= 9)= 1)= 1)= 1)= 1)= 1)= 1)BMS-39886Brahmer [26]INSCLC; RCC; CRC; melanoma2070.3C10 mg/kg every 2 weeksTotal = 61% (= 126)b= 33)= 21)= 19)= 14)= 6)= Theophylline-7-acetic acid 3)Total = 5% (= 11)= 2)= 1)= 1)= 1)= 1)= 1)PembrolizumabHamid (2012) [27]IMelanoma1352 mg/kg every 3 weeks, or 10 mg/kg every two or three 3 weeksTotal = 79% (= 107)= 41)= 28)= 28)= 27)Total = 13% (= 17)= 3)= 2)= 2)= 2)Le (2015) [10]IMetastatic carcinoma with or without mismatch fix deficiency4110 mg/kg every 2 weeksTotal = 98% (= 40)= 13)= 10)= 10)= 6)= 4)Total = 41% (= 17)= 8)= 4)= 7)Robert (2014) [28]IIpilimumab-refractory melanoma1732 or 10 mg/kg every 3 weeksTotal = 82% (= 142)= 60)= 39)= 31)= 22)= 3)= 1)= 7)Total = 12% (= 20)= 5)= Rabbit Polyclonal to B-Raf (phospho-Thr753) 1)= 1)= 1)= 1)Ribas (2015) [29]IIMelanoma3572 or 10 mg/kg every 3 weeks versus standard chemotherapyTotal = 71% (= 252)= 92)= 79)= 29)= 22)= 3)Total = 13% (= 45)= 2)= Theophylline-7-acetic acid 2)= 2)= 2)= 2)= 2)Robert (2015) [2]IIIUntreated melanoma55610 mg/kg every two or three 3 weeks versus ipilimumabTotal = 76% (= 423)= 111)= 79)= 77)= 52)= 27)= 15)= 8)= 6)= 4)Total = 12% (= 65)= 11)= 10)= 8)= 2)= 1)= 1)Garon Theophylline-7-acetic acid (2015) [4]INSCLC4952 or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeksTotal = 71% (= 351)= 96)= 53)= 52)= 48)= 15)= 34)= 18)Total = 10% (= 47)= 19)= 9)= 5)= 4)= 1)PidilizumabArmand (2013) [30]IILymphomac721.5 mg/kg every 42 times 3 dosesTotal = 96% (= 69)= 19)= 18)= 14)= 12)= 10)Total = 54% (= 39)= 14)= 6)Anti-PD-L1 agentDurvalumabSegal [31]IMultiple solid tumorsa34610 mg/kg every 14 days 1 yearTotal = 39% (= 135)= 45)= 30)= 5)= 13)= 8)Total = 6% (= 20)= 2)= 1)= 3)= 1)Rizvi (2015) [32]INSCLC22810 mg/kg every 14 days 1 yearTotal = 93% (= 213)= 9)= 15)= 17)= 3)Total = 53% (= 121)= 1)= 0)= 1)AtezolizumabHerbst (2014) [33]IMultiple solid tumors + hematologic malignancies2770.01C20 mg/kg every 3 weeksTotal = 70% (= 194)= 67)= 33)= 29)= 16)= 10)= 2)Total = 13% (= 35)= 5)= 0)= 0)= 1)= 6)= 2)Powles (2014) [6]IUrothelial carcinoma6815 mg/kg every 3 weeks 1 yearTotal = 57% (= 39)= 8)= 8)= 8)= 3)= 2)Total = 4% (= 3)= 1)= 1)= 1) Open up in Theophylline-7-acetic acid another window aMDS, myelodysplastic symptoms. bInvestigator-reported adverse occasions. cIncluded sufferers with diffuse huge B-cell lymphoma, major mediastinal B-cell lymphoma and changed indolent B-cell lymphoma NSCLC, nonsmall-cell lung tumor; RCC, renal cell carcinoma; CRC, colorectal carcinoma; CRPC, castration-resistant prostate tumor; HCC, hepatocellular carcinoma; GBM, glioblastoma multiforme. Desk 2. Occurrence of adverse occasions in mixture research with ant-PD-1/PD-L1 antibodies and various other therapies, across multiple solid tumors = 53 concurrent, = 33 sequenced)Concurrent (N: 0.3C10 mg/kg every 3 weeks) + I (1C10 mg/kg every 3 weeks) then N + I every three months 8Total = 93% (= 49)a= 29)= 25)= 20)= 18)= 5)= 12)= 11)Total = 53%a (= 28)b= 7)= 7)= 6)= 3)= 2)= 2)Postow et al. [35]IIMelanoma142 (= 95 mixture arm, = 47 I-alone arm)N (1 mg/kg every 3 weeks 4, accompanied by 3 mg/kg every 14 days till development/toxicity) + I (3 mg/kg every 3 weeks 4)Total = 91% (= 86)= 42)= 39)= 22)= 21)= 20)=.